PEG-ASP, Etoposide and Gemcitabine for Natural Killer/T Lymphoma
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive form of non-Hodgkin's
lymphoma and shows extremely poor survival. This prospective pilot study to evaluate the
efficacy and safety of pegylated aspargase(PEG-ASP)combined with etoposide and gemcitabine
(PEG) treatment in this population.